James R Edwards
Overview
Explore the profile of James R Edwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jun I, Choi H, Kim H, Chan Choi B, Chang H, Kim Y, et al.
Bioact Mater
. 2024 Oct;
43:181-194.
PMID: 39386224
Medical stents are vital for treating vascular complications and restoring blood flow in millions of patients. Despite its widespread effectiveness, restenosis, driven by the complex interplay of cellular responses, remains...
2.
Carretero-Iglesia L, Hall O, Berret J, Pais D, Estoppey C, Chimen M, et al.
Nat Cancer
. 2024 Sep;
5(10):1494-1514.
PMID: 39261676
Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3 T cell engager (TCE) co-targeting BCMA and CD38 designed to...
3.
Lewis J, Frost K, Neag G, Wahid M, Finlay M, Northall E, et al.
Cell Rep Med
. 2024 Jul;
5(8):101657.
PMID: 38986622
No abstract available.
4.
The Species Effect: Differential Sphingosine-1-Phosphate Responses in the Bone in Human Versus Mouse
Frost K, Lewis J, Jones S, Edwards J, Naylor A, McGettrick H
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791156
The deterioration of osteoblast-led bone formation and the upregulation of osteoclast-regulated bone resorption are the primary causes of bone diseases, including osteoporosis. Numerous circulating factors play a role in bone...
5.
Lewis J, Frost K, Neag G, Wahid M, Finlay M, Northall E, et al.
Cell Rep Med
. 2024 May;
5(5):101574.
PMID: 38776873
The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM)...
6.
Pouleau B, Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, et al.
Blood
. 2023 May;
142(3):260-273.
PMID: 37192303
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory...
7.
Samakkarnthai P, Saul D, Zhang L, Aversa Z, Doolittle M, Sfeir J, et al.
Aging (Albany NY)
. 2023 May;
15(9):3331-3355.
PMID: 37154858
In addition to reducing fracture risk, zoledronic acid has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate...
8.
Samakkarnthai P, Saul D, Zhang L, Aversa Z, Doolittle M, Sfeir J, et al.
bioRxiv
. 2023 Mar;
PMID: 36865244
In addition to reducing fracture risk, zoledronate has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate with...
9.
Um S, Seo Y, Seo H, Lee K, Park S, Jeon J, et al.
Biomater Res
. 2022 Dec;
26(1):78.
PMID: 36514131
Background: Cells in the human body experience different growth environments and conditions, such as compressive pressure and oxygen concentrations, depending on the type and location of the tissue. Thus, a...
10.
Whitburn J, Rao S, Morris E, Tabata S, Hirayama A, Soga T, et al.
Sci Adv
. 2022 Feb;
8(8):eabf9096.
PMID: 35213227
The spread of cancer to bone is invariably fatal, with complex cross-talk between tumor cells and the bone microenvironment responsible for driving disease progression. By combining in silico analysis of...